100+ Total results for product and free and sample content found
23 Aug 2022
Here's look at five top trends shaping the pharmaceutical industry, assessing their impact on patient engagement and recruitment.
01 Jul 2022
To highlight the growing importance of IO and especially IO combination trials within oncology clinical development, visual trends and key insights about the past 20+ years were compiled.
By Michael McCaughan 16 Jun 2022
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Topic US Election 2020
By Sue Darcey 16 Jun 2022
Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.
By Brian Yang 16 Jun 2022
Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.
Chemist + Druggist Data
11 Mar 2022
We are pleased to announce that from mid-February 2022, C+D Data will provide the UK supply chain with additional product listings and associated PIP-codes for Northern Ireland (NI) and Great Britain (GB.) This solution will allow you to reach the entire UK market quickly and facilitate the ordering and distribution of medicines without disruption to you, and your wholesalers – while ensuring the data’s accuracy, visibility, and long-term management.
By Bridget Silverman 19 Jan 2022
US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: